Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

The EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin and Perjeta – part of the company’s defense against ...

Find Breast Cancer Recurrence Latest News, Videos & Pictures on Breast Cancer Recurrence and see latest updates, news, information from NDTV.COM. Explore more on Breast Cancer Recurrence.

In addition, with the launch of Perjeta in 2012, Kadcyla in 2013, and Phesgo (a subcutaneous coformulation of Herceptin and Perjeta) in 2020, Roche has somewhat refreshed its breast cancer franchise.

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

When breast cancer is diagnosed at stage four, also known as metastatic, that means it has spread to distant parts of the body. While there is no cure, there are still many treatment options at this ...